Terrill K McClanahan

Title: **Terrill K. McClanahan: Innovator in Biomarker Research**

Introduction

Terrill K. McClanahan, based in Sunnyvale, California, is a prominent figure in the field of biotechnology, known for his groundbreaking research and numerous patents. With an impressive portfolio of 24 patents, he has made significant contributions to the development of innovative solutions in the realm of cancer therapy and genomics.

Latest Patents

Among his latest innovations, Terrill K. McClanahan has developed a system and methods for deriving gene signature biomarkers of response to PD-1 antagonists. This gene expression platform combines a set of genes correlated with responses to PD-1 antagonists across various tumor types along with a normalization gene set. The disclosed methods enable the derivation of gene signature biomarkers related to anti-tumor responses and facilitate the testing of patient samples for these predictive markers.

Furthermore, he has pioneered research into blood-based biomarkers of tumor sensitivity to PD-1 antagonists. This patent outlines baseline and on-treatment blood-based gene signature biomarkers that indicate tumor sensitivity to therapy with PD-1 antagonists. The biomarkers include a PD-L1 gene signature or an interferon gamma gene signature for on-treatment analysis, while the baseline gene signature is associated with the oxidative phosphorylation pathway. This invention also provides methodologies and kits for testing tumor samples for these biomarkers and outlines treatment methods based on test results.

Career Highlights

Throughout his career, Terrill K. McClanahan has been associated with major companies in the biotechnology sector, including Schering Corporation and Merck Sharp & Dohme Corporation. His work at these leading organizations has significantly advanced our understanding of cancer therapies and biotechnological applications.

Collaborations

Terrill has collaborated with numerous experts in the field, including notable colleagues Daniel M. Gorman and Erin E. Murphy. These collaborations have enhanced the scope and impact of his research, fostering innovation that bridges different areas of biomedical science.

Conclusion

Through his numerous patents and innovative research, Terrill K. McClanahan continues to influence the landscape of cancer therapy and biomarker discovery. His contributions not only advance scientific knowledge but also hold the potential to improve patient outcomes in cancer treatment methodologies.